Biotech Values

[DewDiligence]

VRTX reports that 58% and 65% of patients in the Telaprevir ADVANCE and ILLUMINATE studies, respectively, stopped treatment at 24 weeks according to the response-guided protocol in these studies:

http://finance.yahoo.com/news/New-Data-From-Phase-3-Studies-bw-2646849491.html?x=0&.v=1

(Unlike the ADVANCE and ILLUMINATE studies in the first-line setting, VRTX's REALIZE study in the second-line setting treated all patients for 48 weeks regardless of the response.)